Skip to main content

Advertisement

Table 1 Baseline demographics

From: Impact of lymphovascular invasion on lymph node metastasis for patients undergoing radical prostatectomy with negative resection margin

   Median (IQR)/n(%)
Age (years)   66(61–71)
Initial PSA (ng/mL)   8.2(5.3–15.5)
Pathologic T stage 2 741(46.3)
  3 825(51.6)
  4 33(2.1)
Lymph node metastasis (−) 1555(97.2)
  (+) 45(2.8)
Pathologic Gleason score ≤6 434(27.1)
  7 780(48.8)
  ≥8 386(24.1)
LVI (−) 1482(92.6)
  (+) 118(7.4)
Margin status (−) 840(52.5)
  (+) 760(47.5)
BCR No 934(58.4)
  Yes 666(41.6)
Distant metastasis Present 1505(94.1)
  Absent 95(5.9)
Cancer-specific mortality Survived 1552(97.0)
  Expired 48(3.0)
Follow-up duration (months)   33.1(18.4–53.8)
  1. LVI lymphovascular invasion; PSA prostate-specific antigen; NHT neoadjuvant hormone therapy; BCR biochemical recurrence